Gritstone bio (GRTS) Set to Announce Earnings on Thursday

Gritstone bio (NASDAQ:GRTS) is set to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Gritstone bio to post earnings of ($0.30) per share for the quarter.

Gritstone bio (NASDAQ:GRTS) last issued its earnings results on Tuesday, March 5th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.10. Gritstone bio had a negative return on equity of 147.22% and a negative net margin of 847.24%. The firm had revenue of $10.38 million during the quarter, compared to the consensus estimate of $4.80 million. On average, analysts expect Gritstone bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gritstone bio Trading Up 8.0 %

Shares of Gritstone bio stock traded up $0.07 on Friday, hitting $0.94. The stock had a trading volume of 480,960 shares, compared to its average volume of 2,709,339. Gritstone bio has a twelve month low of $0.67 and a twelve month high of $3.33. The company has a debt-to-equity ratio of 0.77, a quick ratio of 3.20 and a current ratio of 3.20. The firm has a market capitalization of $100.68 million, a P/E ratio of -0.72 and a beta of 0.64. The stock has a 50 day moving average of $1.75 and a 200 day moving average of $1.91.

Analyst Ratings Changes

Several equities research analysts recently issued reports on GRTS shares. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Gritstone bio in a report on Wednesday, March 6th. JMP Securities raised their target price on Gritstone bio from $4.00 to $5.00 and gave the company a “market outperform” rating in a research report on Tuesday, April 2nd.

Gritstone bio Company Profile

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.